Market capitalization | $111.90m |
Enterprise Value | $21.24m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.11 |
P/S ratio (TTM) P/S ratio | 11.09 |
P/B ratio (TTM) P/B ratio | 0.55 |
Revenue growth (TTM) Revenue growth | 29.94% |
Revenue (TTM) Revenue | $10.09m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
1 Analyst has issued a forecast Tonix Pharmaceuticals Holding Corp.:
1 Analyst has issued a forecast Tonix Pharmaceuticals Holding Corp.:
Dec '24 |
+/-
%
|
||
Revenue | 10 10 |
30%
30%
|
|
Gross Profit | -1.08 -1.08 |
12%
12%
|
|
EBITDA | -74 -74 |
35%
35%
|
EBIT (Operating Income) EBIT | -78 -78 |
34%
34%
|
Net Profit | -130 -130 |
11%
11%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.
Head office | United States |
CEO | Seth Lederman |
Employees | 81 |
Founded | 2007 |
Website | www.tonixpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.